Companies / Crinetics Pharmaceuticals, Inc. / Activity
Activity — Crinetics Pharmaceuticals, Inc.
13 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q3 2025 as of | Farallon Capital Management LLC 13F manager | New | Common stock | $240.32M | +5.8M | 5,770,098 5.44% of shares | high |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | New | Common stock | $24.85M | +684K | 684,108 0.64% of shares | medium |
| Q1 2026 as of | Campbell & CO Investment Adviser LLC 13F manager | New | Common stock | $3.04M | +84K | 83,617 0.08% of shares | low |
| Q1 2026 as of | Capital Fund Management S.A. 13F manager | New | Common stock | $1.12M | +31K | 30,728 0.03% of shares | low |
| Q1 2026 as of | Sanders Morris Harris LLC 13F manager | New | Common stock | $766.4K | +21K | 21,100 0.02% of shares | low |
| Q1 2026 as of | Federated Hermes Inc 13F manager | New | Common stock | $590.1K | +16K | 16,248 0.02% of shares | low |
| Q1 2026 as of | Magnetar Financial LLC 13F manager | New | Common stock | $345.7K | +10K | 9,518 <0.01% of shares | low |
| Q3 2025 as of | Leonteq Securities AG 13F manager | New | Common stock | $293.6K | +7K | 7,050 <0.01% of shares | low |
| Q1 2026 as of | Gabelli Funds LLC 13F manager | New | Common stock | $217.9K | +6K | 6,000 <0.01% of shares | low |
| Q2 2025 as of | Elevation Point Wealth Partners, LLC 13F manager | New | Common stock | $100.1K | +3K | 3,481 <0.01% of shares | low |
| Q3 2024 as of | Danske Bank A/S 13F manager | New | Common stock | $35.8K | +700 | 700 <0.01% of shares | low |
| Q1 2026 as of | Algert Global LLC 13F manager | New | Common stock | $3.6K | +98K | 97,802 0.09% of shares | low |
| Q2 2026 as of | CVA Family Office, LLC 13F manager | New | Common stock | $1.1K | +29 | 29 <0.01% of shares | low |